TNFRSF10B, a Therapeutic Target for Oral Squamous Cell Carcinoma Through Integrated Bioinformatics and Preliminary

Yingshun Yang1, Zhizheng Zhuang2, Yan Hu2

  • 1Department of Oral and Maxillofacial Surgery, Hebei Eye Hospital, Xingtai, China.

Insights

Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) drives oral cancer progression by impairing apoptosis. Targeting TNFRSF10B may restore apoptosis and enable precision therapy for oral squamous cell carcinoma (OSCC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Oral Squamous Cell Carcinoma (OSCC) development is critically influenced by apoptosis regulators.
  • Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) is identified as a key player in OSCC apoptosis regulation.

Purpose of the Study:

  • To identify pivotal genes regulating OSCC progression.
  • To investigate the role of TNFRSF10B in OSCC development, prognosis, and as a potential therapeutic target.

Main Methods:

  • Differential gene expression analysis and weighted gene co-expression network analysis.
  • Lasso regression, Cox modeling, and validation in The Cancer Genome Atlas (TCGA) and clinical samples.
  • Protein-protein interaction network construction, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and in vitro siRNA-mediated gene knockdown experiments.

Main Results:

  • TNFRSF10B was identified as a core gene significantly associated with unfavorable OSCC prognosis, exhibiting strong diagnostic power.
  • Overexpression of TNFRSF10B correlated with advanced clinical stage, nodal metastasis, chemoresistance, and was implicated in extrinsic and necroptotic apoptosis pathways.
  • Knockdown of TNFRSF10B suppressed cell viability and induced apoptosis by modulating Bax, Bcl-2, and Caspase-3/PARP activation.

Conclusions:

  • TNFRSF10B promotes OSCC progression by inhibiting apoptosis, with its overexpression linked to poor prognosis.
  • TNFRSF10B represents a potential diagnostic biomarker and therapeutic target for OSCC.
  • Targeting TNFRSF10B holds promise for restoring apoptosis and advancing precision therapy in OSCC.